Cerebrolysin Research Peptide

In that 2013 study, published in Stroke, Zhang and colleagues worked first with neural progenitor cells taken from the subventricular zone of adult rats, one of the few areas of the adult brain that keeps making new cells. Cerebrolysin increased both the multiplication of these cells and their development into neurons and myelin-forming oligodendrocytes, and it raised levels of Sonic hedgehog and its receptors, Patched and Smoothened. When the team blocked Smoothened with the drug cyclopamine, those effects disappeared.

The same pattern held in rats after embolic stroke. Treatment started 24 hours after the stroke increased new cell production in the subventricular zone and led to more neurons, more oligodendrocytes and more remodelling of nerve fibres around the damaged area, with clear improvements on neurological tests from the third to the fifth week. Blocking the Sonic hedgehog pathway reversed those gains, which is why this study is often cited as evidence for a specific mechanism behind what is otherwise a very complex mixture.

For decades, Cerebrolysin’s exact chemical make-up was not publicly described. In 2015, a team writing in Drug Testing and Analysis used liquid chromatography and high-resolution mass spectrometry to analyse a sample bought online, and identified 638 different peptides (Learn more). Most came from common structural brain proteins, mainly the alpha and beta chains of tubulin, actin and myelin basic protein.

Just as interesting was what they did not find. There were no fragments of the well-known growth factors often mentioned in connection with Cerebrolysin, such as BDNF, NGF, GDNF or CNTF. The authors suggested that its reported activity may come from previously unknown short peptides released from larger proteins during digestion. This matters for laboratory work: a peptide mixture cannot be checked against one expected mass in the way a single synthetic peptide can, so batch documentation plays an even bigger part.

The CARS trial, published in Stroke in 2016, studied Cerebrolysin alongside a standard rehabilitation programme in patients who had recently had a stroke, starting treatment 24 to 72 hours after onset. At 90 days, arm and hand function, measured with the Action Research Arm Test, was markedly better in the Cerebrolysin group than with placebo, and a combined measure across 12 outcome scales also favoured Cerebrolysin. Fewer than 4% of patients stopped early, and safety was comparable with placebo (Learn more).

The CAPTAIN programme tested Cerebrolysin as an add-on to usual care after moderate to severe traumatic brain injury. A prospective meta-analysis of the two randomised, double-blind trials, covering 185 patients and published in Neurological Sciences in 2021, found a small-to-medium effect in favour of Cerebrolysin across a combined set of functional and neuropsychological scales, statistically significant at both 30 and 90 days, with safety comparable between the groups (Learn more).

Cerebrolysin has also been studied in mild-to-moderate Alzheimer’s disease. A 2015 meta-analysis of six randomised, placebo-controlled trials, published in Dementia and Geriatric Cognitive Disorders, found that Cerebrolysin significantly improved cognitive function at four weeks and global clinical change at four weeks and six months compared with placebo, with a safety profile comparable to placebo (Learn more). Together with the rodent findings on new brain-cell growth, this makes Cerebrolysin one of the most widely studied compounds in neurorecovery research.